England and Wales reject Leo Pharma's eczema drug

The National Institute for Health and Care Excellence (NICE) has decided not to recommend Leo Pharma’s atopic dermatitis treatment tralokinumab.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
by ulrich quistgaard, translated by daniel pedersen

The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), has announced in a press release that it does not recommend Leo Pharma’s Adtralza (tralokinumab) as a treatment for atopic dermatitis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading